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Abstract
The rapid progress in the field of genomics is increasing our knowledge of multi-gene diseases.
However, any realistic hope of gene therapy treatment for those diseases needs first to address
the problem of co-ordinately co-expressing several transgenes. Currently, the use of internal
ribosomal entry sites (IRESs) is the strategy chosen by many researchers to ensure co-expression.
The large sizes of the IRESs (~0.5 kb), and the difficulties of ensuring a well-balanced co-expression,
have prompted several researchers to imitate a co-expression strategy used by many viruses: to
express several proteins as a polyprotein. A small peptide of 18 amino acids (2A) from the foot-
and-mouth disease virus (FMDV) is being used to avoid the need of proteinases to process the
polyprotein. FMDV 2A is introduced as a linker between two proteins to allow autonomous intra-
ribosomal self-processing of polyproteins. Recent reports have shown that this sequence is
compatible with different sub-cellular targeting signals and can be used to co-express up to four
proteins from a single retroviral vector. This short peptide provides a tool to allow the co-
expression of multiple proteins from a single vector, a useful technology for those working with
heteromultimeric proteins, biochemical pathways or combined/synergistic phenomena.
Introduction
For the last 20 years, the gene therapy field has centred
many of its efforts on finding ways to deliver a therapeutic
gene to certain target cells in order to produce a therapeu-
tic result. It was soon clear that it was necessary to deliver
at least two genes, because a reporter/marker gene was
needed in order to track the expression of the therapeutic
gene (normally not easy to detect). There has been a large
increase in vector development during these years, with
the appearance of many new viral and non-viral vectors.
However, since the late 1980s, few improvements have
been made 'inside' those vectors. The linkage of the two
genes of interest (therapeutic and reporter) has remained
the same. The different strategies known for co-expression
were reported during the 1980s -splicing, multiple pro-
moters, fusions, reinitiation and IRESs-, at the same time
that the first gene therapy experiments were being per-
formed (for a review [1]). During the 1990s, nearly all
those strategies were abandoned in favour of the IRESs. In
bicistronic mRNAs bearing an IRES sequence, the first cis-
tron is translated by scanning ribosomes that enter via the
5' end. The cloning of an IRES sequence downstream of
the first cistron, allows the internal entry of ribosomes
that translate the second cistron. As each cistron is trans-
lated from a different translational initiation event, both
translations are uncoupled, and the proteins are not
obtained in an equimolecular proportion ("imbalance")
leading to a large excess of the first protein.
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The drive to co-express more than two genes, opening the
door to therapies for muti-gene deficiencies, was halted by
the inability of vector technology to guarantee a reliable
co-expression. Nevertheless, IRESs were the first strategy
that met with some success, and several polycistronic vec-
tors able to co-express up to 4 genes were developed dur-
ing the 1990's [2]. However, two main problems blocked
the successful use of large and complex polycistronic vec-
tors: the large size and imbalance of most IRESs which
makes it very difficult to predict the level of expression of
the downstream cistron [3].
This commentary discusses several recent publications
that use self-processing polyproteins as a novel strategy
for co-ordinated co-expression of several genes.
Discussion
Although gene therapy has employed the viruses as vec-
tors, the co-expression strategies previously described
have not taken advantage of the dominant ways in which
viruses achieve co-expression in cells. It is the polyprotein
strategy that many viruses use to co-express most of their
proteins, or even all of them (as in picornaviruses). Not
surprisingly, this strategy is indeed used by cells, although
not very often, in particular for the co-ordinated secretion
of different proteins and peptides. Recently, several
groups have been trying to utilize this co-expression strat-
egy. One of the possibilities is to introduce the target site
for a cellular proteinase between two cistrons cloned in
frame forming a single open reading frame (ORF; [4]). In
this way the polyprotein is synthesized as a fusion protein
that post-translationally is proteolytically cleaved to yield
the discrete proteins of interest. Unfortunately, this strat-
egy has several practical difficulties: (1) the polyprotein to
be cleaved must reside, or at least pass through, the same
compartment as the proteinase, (2) the cleavage is not
always independent of the context, (3) the cleavage may
be incomplete and unpredictable, (4) efficient cleavage
will only be produced in cells actively expressing the pro-
teinase, and (5) the post-translational cleavage is not
compatible with all possible sub-cellular targetings. In
many ways, a co-translational strategy such as reinitiation,
which would be independent of cellular or viral factors,
would be desirable. In reinitiation, ribosomes first trans-
late an upstream cistron, although highly inefficiently,
then resume translation of the second, downstream, cis-
tron. Reinitiation was indeed tried in the 1980s, but the
large imbalance makes it unsuitable for co-expression of
even two genes (reviewed in [1]).
The foot-and-mouth disease virus (FMDV) 2A sequence as 
a co-expression tool
Picornaviruses, the same family of viruses to first provide
the IRESs, encode all their proteins in a long single ORF
that is cleaved post-translationally by viral proteinases.
However, it was described in the 1980's that at one posi-
tion, the polyprotein of some picornaviruses (such as
FMDV) underwent a rapid co-translational self-process-
ing. It was soon realised that the key was a small 18aa pep-
tide (2A) that directed its own separation from the
growing polyprotein. During the last decade, this mecha-
nism has been studied in detail, resulting in a simple
model: the small 2A peptide, during its translation, inter-
acts with the exit tunnel of the ribosome to induce the
"skipping" of the last peptide bond at the C-terminus of
2A. The crucial point is that the ribosome is able to con-
tinue translating the downstream gene, after releasing the
first protein fused in its C-terminus to 2A (reviewed in
[5]). This type of sequence has been termed CHYSEL (cis-
acting hydrolase element). From a biotechnological
standpoint, all that is needed is to clone the coding
sequence of 2A, followed by the codon for the first amino
acid of the next FMDV protein (2B), in frame between the
two genes one wishes to co-express. The synthesis of the
peptide bond between the last amino acid (Gly) of 2A and
the first (Pro) of 2B is skipped, producing an upstream
protein with a C-terminal tail of 18aa (2A) and a down-
stream protein with a Pro at the N-terminus. The extra
sequences have minimal effect on the activity of most pro-
teins and none on their stability. In fact, the 2A peptide
has been used as an efficient tag for immunoprecipitation
and Western blotting, although commercial antibodies
are not yet available. Interestingly, additional CHYSEL
sequences have been found in viruses other than FMDV
(for a review of these "2A-like" sequences, see [5]).
Broad applicability of 2A
The initial publications using this strategy have shown
that 2A skipping can be used in the typical viral vectors
used for gene therapy (retrovirus and adeno-associated
virus) to reliably co-express many reporter proteins (neo-
mycin phosphotransferase, NEO; puromycin N-acetyl
transferase, PAC; green fluoresecent protein, GFP, etc) and
therapeutic proteins (Herpes simplex virus-1 thymidine
kinase, HSV1TK; interleukin-12, IL-12; viral antigens, etc.)
in transient transduced or stable cells lines and in animals.
A full list of publications using 2A is available on the web
[6]. Several publications in the past few months have
shown the potential of this new co-expression strategy [7-
9].
Co-ordinating the co-expression of all your genes
Up to four genes have been successfully co-expressed from
plasmids and retrovirus using several copies of the FMDV
2A or other 2A-like sequences (to avoid direct repeats in
retroviruses) [8,9]. Not only was co-expression effective,
its co-ordination was also apparent [7,9] (Fig. 1), and the
imbalance in the level of the proteins expressed was low
(determined to 1.2 [8]). These properties allowedGenetic Vaccines and Therapy 2004, 2:13 http://www.gvt-journal.com/content/2/1/13
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Co-ordinated co-expression to different compartments in HeLa cells Figure 1
Co-ordinated co-expression to different compartments in HeLa cells. A single ORF was designed with the fluores-
cent genes eyfp and ecfp plus the puromycin resistant gene pac [9]. These genes were cloned flanking FMDV 2A sequences. An 
internal signal-anchor from the human β-1,4 galactosyltransferase (GT) was fused to the 5' end of the ecfp for Golgi targeting. 
During its translation, the self-processing of this polyprotein produced EYFP-2A that diffused to the cytoplasm and nucleus 
(due to its small size), while GT-EYFP-2A was co-translationally targeted to the Golgi apparatus by the GT signal (some protein 
also stays in the endoplasmic reticulum, due to the continuous cycling between these compartments). Two fields are shown, in 
both cases the cell on the left shows a high level of expression of both proteins that were expressed at lower levels in the cell 
on the right, illustrating the co-ordination obtained with the 2A co-expression strategy. PAC was able to confer resistance to 
puromycin. Images were taken 48 hours post-transfection. Bar represents 10 µm.
EYFP ECFP PAC 2A
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polycistronic vectors bearing pac in the last position to
easily generate stable cell lines co-expressing two
upstream genes [7,9].
Putting your proteins where they should be
The CHYSEL strategy of co-expression is also compatible
with the most disparate sub-cellular localisations [7-10].
Proteins processed by 2A from polyproteins were targeted
to the cytosol, nucleus, mitochondria, endoplasmic retic-
ulum, Golgi apparatus, plasma membrane (both, by
transmembrane proteins and by cytosolic attachment due
to myristoylation) and the extra-cellular compartment.
Post-translationally targeted cytosolic proteins as well as
co-translationally secreted and transmembrane proteins
type I, II and III, have been successfully co-translated.
Only one combination of co-translational signals was not
correctly targeted [9].
Designing complex polyproteins for multi-gene deficiency
The results reported in reference [8] should be particularly
interesting for researchers in the gene therapy field. They
provide a good example of the potential of the 2A co-
expression strategy, introducing up to four genes in a sin-
gle vector. Furthermore, they show the utility of this strat-
egy to reconstruct a very delicate heteromultimeric protein
complex on the cell surface (T-cell receptor:CD3 complex,
TCR:CD3; Fig. 2A). It is known that all six subunits are
necessary for the efficient formation of the TCR:CD3 com-
plex and just two retroviral vectors were sufficient to
reconstruct it in transfected 293T or infected 3T3 cells: one
encoding both subunits of the T-cell receptor and the
other the four subunits of the CD3 complex (Fig. 2B).
Lethally irradiated CD3ε∆P/∆P × CD3ζ -/- mice (lacking all
four CD3 subunits) were transplanted with bone marrow
from wt C57BL/6 mice or CD3ε∆P/∆P × CD3ζ -/- mice trans-
duced with a retrovirus encoding the four CD3 subunits,
and in both cases TCR surface expression was detected and
the T cells proliferated normally after immune stimula-
tion. Bone marrow from CD3ε∆P/∆P × CD3ζ -/- mice with-
out CD3 transduction did not restore T-cell development.
T cells were also reconstituted in sub-lethally irradiated
RAG-1-/- mice (lacking mature T and B lymphocytes) in
which bone marrow from CD3ε∆P/∆P mice (lacking CDε
and with a severe inhibition of CD3γ and CD3δ), trans-
duced with a retrovirus encoding these three subunits (via
two 2A sequences), was used for a transplant into the
RAG-1-/- mice. The same experiment using three vectors
encoding the CD3 subunits separately was unsuccessful.
Conclusions
The development of FMDV 2A as a cloning tool is an
example of how dangerous pathogenic viruses can be har-
nessed by biotechnology for human benefit. Their molec-
ular "tricks" (as IRES or CHYSEL sequences) are gradually
becoming part of the biotechnologists' toolbox. The
development of the polycistronic vectors here discussed is
a big step forward, a decade and a half after the launching
of the very first gene therapy trial with the aim of introduc-
ing in blood cells just a single therapeutic gene, adenosine
deaminase (ADA), and the NEO marker [11]. These
results represent a considerable advance in the correction
Self-processing polyproteins to reconstruct the TCR:CD3  complex Figure 2
Self-processing polyproteins to reconstruct the 
TCR:CD3 complex. (A) Schematic diagram of the 
TCR:CD3 complex spanning the cytoplasmic membrane. The 
T-cell receptor (TCR) is formed by two subunits and the 
other four proteins assemble in three dimers to form the 
CD3 complex. The square boxes in the cytoplasmic 
sequences of the CD3 subunits represent the immunorecep-
tor tyrosine-based activation motifs (ITAMs). (B) To express 
the TCR:CD3 complex in cells, two retroviral vectors were 
designed to carry the two ORFs drawn here [8]. In the ret-
rovirus encoding the four CD3 subunits, three different 2A 
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of diseases that involve heteromultimeric proteins, several
enzymes involved in a biochemical pathway or various
proteins for combined/synergistic effects. 2A is not a
magic tool that is going to solve all our problems, but it
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